Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Mar 2026 is 80.34% vs 23.59% in Mar 2025
Consolidate Net Profit
YoY Growth in quarter ended Mar 2026 is 488.57% vs 74.36% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Mar 2026 is 1,313.04% vs 112.50% in Mar 2025
Interest
YoY Growth in quarter ended Mar 2026 is 10.81% vs 32.14% in Mar 2025
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025
Compare Quarterly Results Of Chengdu Olymvax Biopharmaceuticals, Inc. With
Quarterly - Net Sales
QoQ Growth in quarter ended Mar 2026 is -19.98% vs -1.94% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 80.34% vs 23.59% in Mar 2025
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Mar 2026 is 207.94% vs -174.34% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 488.57% vs 74.36% in Mar 2025
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Mar 2026 is 346.21% vs -124.13% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 1,313.04% vs 112.50% in Mar 2025
Quarterly - Interest
QoQ Growth in quarter ended Mar 2026 is 7.89% vs 11.76% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 10.81% vs 32.14% in Mar 2025
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025






